4526.T

Corporate Identity and Core Philosophy

• Founded in 1949, listed on the Tokyo Stock Exchange Prime Market, with 2025 March fiscal year consolidated revenue of 95.5 billion yen, positioning it as a mid-sized food manufacturer.
• Core corporate philosophy rooted in "effective utilization of natural resources", inherited from its founding business of extracting vitamin A from discarded fish offal and livers.
• Operates three core product areas: Food, Improvers, and Healthcare, with improvers accounting for more than half of total product sales, followed by food, then healthcare; healthcare has a relatively high profit margin despite its lower sales share.

Core Product Segment Details

• Food: Sells consumer products (dressings, wakame products like Fuewake-me-chan) to supermarkets for household use, and bulk extracts, dried/frozen seaweed products to the food service, school lunch, and processed food industries for commercial use.
  • Conducts advanced seaweed sustainability research: wakame seed breeding, on-land seaweed aquaculture facilities, and large-scale kelp farming for blue carbon CO2 absorption, with Riken Vitamin leading this research among domestic Japanese companies across short/medium/long-term timelines.
• Improvers: A collective term for processed food raw materials that add functional properties to food, Riken Vitamin holds the top market share for food emulsifiers and gardenia yellow pigment, and holds a very high market share for anti-fog additives for food packaging plastic film.
  • Key benefits include maintaining bread softness over time, improving noodle looseness, reducing production line stickiness and material loss to improve production efficiency, which benefits both manufacturers and end consumers.
• Healthcare: Core strength is vitamin E, holding a combined 40%+ market share with peer companies, and has expertise in blending and stabilizing mixed vitamins for use in protein and complete nutrition products. Also extracts crocetin from gardenia fruit, which has approved functions of improving sleep quality and assisting eye focus adjustment, with growing adoption in health foods and retail beverages.
  • Long-held microencapsulation technology traps unstable substances (such as vitamins or flavor compounds) in a hard dry capsule, used to preserve freshness and enable controlled release in food, cosmetic, and pharmaceutical applications.

Mid-Term Management Plan (Chuki Keiei Keikaku 2027)

• Long-term 2035 March fiscal year targets: 135 billion yen revenue, 10% operating profit margin, 10-12% ROE, and 35% overseas sales ratio.
• 3-year mid-term plan ending 2028 March fiscal year has two core themes: strengthening domestic sustainable profit generation, and building a new overseas structure for future growth; mid-term targets are 110 billion yen revenue, 10 billion yen operating profit, and 10%+ ROE.
• Domestic Strategy:
  • Domestic Food Business: Aims to outgrow the overall processed food market amid population decline; focuses on developing new market-creating products for household goods, and growing sales in expanding sectors (prepared meals, ready-to-eat, central kitchens, frozen meals) for commercial food, while strengthening proposals for raw material supply issues, food loss reduction, and the health product market.
  • Domestic Chemical Products Business: Focuses on existing core strengths amid industry-wide oversupply from overseas manufacturers, prioritizes environmental initiatives using non-petroleum derived raw materials to align social problem solving with business growth.
• Overseas Strategy: Core theme is shifting from commodity to specialty products; major challenges require large capital investment in production equipment, alongside strengthening sales, quality assurance, and back-office functions.
• Financial Strategy and Capital Allocation:
  • Total 25 billion yen capital expenditure planned over the 3-year plan: 13 billion yen for domestic facilities (focused on aging equipment replacement and labor-saving automation to address labor shortages) and 12 billion yen for overseas facilities (largely allocated to a Malaysian plant for the improver segment); the policy of positioning overseas as a long-term growth driver remains unchanged.
  • Total 12.4 billion yen planned shareholder return over 3 years: combines 2 billion yen in ongoing share buybacks and 10.4 billion yen in planned dividends; dividend payout ratio has been raised to 40%+, and the company prioritizes stable dividends with no planned changes to this policy.
  • Capital investment is funded by an expected 28 billion yen in operating cash flow and 9 billion yen from reducing cross-held policy shares.

Recent Operational Updates

• Completed major facility upgrades at the aging Tokyo Plant, including a new pharmaceutical microcapsule building (2022) and a new vitamin blending building (2024), with similar upgrades planned for other domestic plants.
• Popular twice-yearly shareholder benefit program offers company product packages based on holding size and tenure, with regular content updates to engage shareholders.

• The 2026 March fiscal year full-year consolidated earnings guidance was revised downward in the third quarter, driven by two factors: weak overseas business performance and increased asset retirement obligation expenses.
• The forecast for the Overseas Business segment was revised from a profit to an operating loss of 550 million yen for the 2026 March fiscal year.
• The 2028 March fiscal year (mid-term plan end) Overseas Business operating profit target of 1.6 billion yen remains unchanged for now; management notes that market conditions have changed significantly, and a potential update may be announced at the full-year earnings announcement if action is deemed necessary.
• The company maintains its long-term target of reaching 100 billion yen market capitalization (equivalent to approximately 3,400 yen per share), with further growth targeted beyond this level in the medium to long term.
• Management maintains its commitment to a 40%+ dividend payout ratio and a stable dividend policy; the 2026 March fiscal year planned dividend of 110 yen per share is maintained despite the downward earnings revision.

Riken Vitamin reports its business segments by sales destination, with the following revenue contribution breakdown: 1. Domestic Food Business: Accounts for approximately 70% of total consolidated revenue. Excluding the impact of asset retirement obligation estimation changes, operating profit increased slightly year-over-year in the 2026 March fiscal year forecast. Its internal composition is 100% food for household products, a high share of food plus a portion of improvers for commercial food, and mostly improvers and healthcare products with minimal food share for processed food raw materials. 2. Domestic Chemical Products and Other Business: Accounts for less than 10% of total consolidated revenue. This segment is centered on improvers. 3. Overseas Business: Accounts for approximately 25% (one quarter) of total consolidated revenue, and is also centered on improvers, with 10% of its revenue coming from food (mostly pork extract). For the 2026 March fiscal year (the current forecast period), the segment posted a forecast operating loss of 550 million yen, down from an 1.1 billion yen operating profit in the previous period.

• Overseas Market Risks: All overseas markets outside the U.S. are facing challenging conditions: 1) China: Economic slowdown has reduced sales at existing clients, with demand concentrated in low-priced products, making it harder for Riken Vitamin's high value-added products to gain adoption, following completion of a new Chinese factory just before the slowdown. 2) Southeast Asia and Europe: New entrants and expanded capacity from existing producers have led to massive oversupply of commodity products, intensifying price competition far faster than originally expected, hitting commodity-focused regions hard. Only the U.S. market is performing well, with growing demand for pork extract for ramen soup base and new large clients emerging.
• Domestic Asset Retirement Obligation Risk: After demolishing an asbestos-containing building in the 2025 March fiscal year, actual demolition costs far exceeded original estimates. Reassessment of all domestic buildings led to a 1.5 billion yen increase in total asset retirement obligation, with 880 million yen recognized in the 2026 March fiscal year; remaining unrecognized increases will gradually reduce profit in future periods. This is a non-cash expense.
• Raw Material Procurement Risk: Seaweed production declines threaten stable supply for the company's seaweed-focused food products; the company has strengthened procurement teams and is conducting extensive R&D to address this challenge.
• Domestic Market Risks: Domestic population decline, rising raw material and labor costs, and industry-wide oversupply in the chemical products sector create ongoing headwinds for domestic business.
• Internal Operational Risks: Aging domestic production facilities and widespread labor shortages are key internal challenges, which the company is addressing through targeted capital investment for aging replacement and labor-saving automation.

Q: What is the current status of price pass-through for rising costs, and which sectors have the strongest resistance to price increases?

A: The company's policy is to fully pass through increased costs, but BtoC household food products are very price sensitive, so price increases directly hit sales volumes. For this reason, the company is being very cautious about household product price increases. For BtoB business, the company has been able to progress price pass-through with client understanding, though there is some time lag for implementation.

Q: Can Riken Vitamin rebound in China using its proprietary technology, given the current challenging market conditions?

A: The company is in the process of shifting production from an old factory to a newly completed factory in China, and is currently progressing proposals for new clients and new products, with some progress already. While existing products are underperforming and overall sales remain weak, the company expects economic cycles to eventually improve, and will continue to promote its unique added value to clients, focusing on high value-added products rather than competing on low prices. The company's core strength is its "application capability" to solve client specific problems, which it will leverage to win adoption in the Chinese market.

Q: Does the new Chinese factory improve operational efficiency, and can it drive future profit improvements?

A: The new factory is designed to operate without increasing headcount, so it is very efficient and high quality. While it is currently being impacted by the economic slowdown, improved yield and lower costs should drive higher profits once market conditions improve, so the company remains optimistic about its long-term impact.

Q: Can you explain the competitive advantage of Riken Vitamin's microencapsulation technology?

A: Microencapsulation traps active ingredients in small particles, and is a niche market with limited competitor entry currently. The technology is very versatile: it can control fragrance release in confectionery, control dissolution rate for pharmaceutical products to target specific areas of the body, and can be applied across many other industries beyond food and pharma. This versatility makes it a very promising technology, and the company is actively exploring new applications and client proposals.

Q: What is the company's approach to increasing the overseas sales ratio, and what are the key challenges?

A: The company is currently preparing to shift to specialty products aligned with the mid-term plan, with core investment focused on production equipment centered on the Malaysian plant. To be closer to local markets and reduce logistics and tariff costs, the company is also working to secure production capacity (including third-party contracted production) in regional markets. For example, the company started contracted local production in Vietnam in December last year, and plans to expand this model to produce specialty products regionally to enable better localized service.

Q: With PER at 11.8x and PBR at 1.2x below market average, what valuation does management consider appropriate?

A: The company's medium-term target market capitalization is 100 billion yen, which equals approximately 3,400 yen per share. The company views this as a waypoint, and aims to grow further beyond this level in the medium to long term.

Q: How much price revision is already reflected in forecasts, and is there room for further price increases?

A: Price revisions are reflected in forecasts with a slight time lag. In the current inflationary environment, the company's policy is to pass through higher costs, but remains cautious about household product price increases due to their large impact on sales volume.

Q: How much profit contribution can we expect from blue carbon and seaweed research in the future?

A: The profit contribution of blue carbon is highly uncertain with many variable factors, so it cannot be estimated at this stage. However, Riken Vitamin conducts more advanced research in this area than any other Japanese company, and the company aims to fully monetize this research at the appropriate time in the future.

Q: Are there any planned new country market entries, or new markets under consideration?

A: There are no plans for entry into entirely new countries, but the company established new sales subsidiaries in Thailand and Vietnam last year. The company is also exploring securing production capacity (including contracted production) close to consumer markets, especially in Southeast Asia and North America.

Q: Will there be a viewer giveaway of the shareholder benefit products featured today?

A: There is no planned giveaway, we apologize for that.

Q: What are the key internal challenges facing the company, and any planned reforms?

A: The key internal challenges are aging production facilities and labor shortages. The company is addressing these through capital investment for aging facility replacement and labor-saving automation, and is progressing these initiatives currently.